The epidemiology of @entity6 in XXXX .

@entity1 @entity6 @entity914 @entity161 @entity716
@entity6 is highly prevalent in @entity1 with @entity914 , including @entity161 and @entity914 . Exact prevalence is difficult to estimate, since @entity6 is often underdiagnosed in @entity1 with @entity716 . Results of several studies show that the prevalence of @entity6 exceeds that in the general population, with documented prevalence in those with @entity716 ranging from 1  26% to 50% across studies (median 13%). The association between @entity6 and @entity716 is complex and multifactorial. Many of the traditional risk factors for disease have increased prevalence in @entity1 with @entity914 . In addition to these traditional risk factors, @entity1 with @entity716 have unique risks that might have additive or even synergistic effects. These risks include the use of antipsychotic medication, the effects of adverse social determinants of health, and genetic loading. Despite evidence that rates of @entity6 are increased in individuals with @entity716 , many of these @entity1 are not diagnosed or treated, resulting in increased @entity6 -associated morbidity and mortality. Specific @entity1 factors, provider issues, and systems-level factors contribute to the treatment gap. Interventions at both the clinical and public health levels are needed to successfully address this problem.
